Galectin Therapeutics Inc (GALT) FinancialsGALTGalectin Therapeutics Inc

In the context of the broader market, GALT competes directly with industry leaders such as EDIT and ZURA. With a market capitalization of $321.71M, it holds a significant position in the sector. When comparing efficiency, GALT's gross margin of N/A stands against EDIT's 100.00% and ZURA's N/A. Such benchmarking helps identify whether Galectin Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Galectin Therapeutics has reported consistent losses, with a net income loss of $9.11 million in Q2 2026, a 21% increase from the previous year. The company's EPS for Q2 2026 is -0.14, reflecting ongoing financial struggles.